Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q4 2022 Earnings Conference Call February 23, 2023 8:00 AM ET
Company Participants
Jessi Rennekamp - Senior Director, Corporate Communications
Brian Goff - CEO
Sarah Gheuens - CMO & Head, R&D
Tsveta Milanova - CCO
Cecilia Jones - CFO
Conference Call Participants
Chris Raymond - Piper Sandler
Marc Frahm - Cowen
Mary Kate - Bank of America
Tessa Romero - J.P. Morgan
Greg Renza - RBC
Mark Breidenbach - Oppenheimer
Danielle Brill - Raymond James
Operator
Good morning, and welcome to Agios Fourth Quarter and Year-End 2022 Conference Call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session at the end. Please be advised that this call is being recorded at Agios request.
I would now like to turn the call over to Jessi Rennekamp, Senior Director of Corporate Communications. Please go ahead.
Jessi Rennekamp
Thank you, Operator. Good morning, everyone, and welcome to Agios fourth quarter and year-end 2022 conference call. You can access slides for today's call by going to the Investors section of our website, agios.com.
With me on the call today with prepared remarks are Brian Goff, our Chief Executive Officer; Dr. Sarah Gheuens, our Chief Medical Officer and Head of Research and Development; Tsveta Milanova, our Chief Commercial Officer; and Cecilia Jones, our Chief Financial Officer.
Before we get started, I would like to remind everyone that some of the statements we make on this call will include forward-looking statements. Actual events and results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties and other factors, including those set forth in our most recent filings with the SEC and any other future filings that we may make with the SEC.
With that, I will turn the call over to Brian.
Brian Goff
Good morning, everyone, and thank you for joining us.
Agios is the pioneering leader in PK activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. Driven by the cross-functional commitment of the Agios team, we made tremendous progress over the past year toward our goal of building a PK activation franchise focused on hematologic diseases that share a common underlying pathophysiology, limited treatment options, and profound unmet need.
In particular, I'd like to highlight the excellence in execution displayed across our research and development team to bring forward PYRUKYND our first-in-class PK activator as the first and only approved disease modifying therapy for adults living with PK deficiency. PYRUKYND was approved in the U.S., EU, and Great Britain in 2022 and represents the cornerstone of our growing PK activation franchise with the potential for two additional indications by 2026.